1[2]Guang Yan,Henan Li,Ruhua Zhang,et al.Preparation and evaluation of a sustained-release formulation of nifedipine HPMC tablets.Drug Deve Ind Pharm,2000,26 (6):681-686. 被引量：1
3He J, Gu D, Chen J, et al. premature deaths attributable to blood pressure in China: a prospective cohort study [J]. The Lancet, 2009,374( 9703): 1765-1772. 被引量：1
4Staessen JA, Wang J, Bianchi G, et al. Essential hypertension [J]. The Lancet, 2003, 361( 9369):1629-1641. 被引量：1
5YoonSS, Ostchega Y, Louis T. Recent trends in the prevalence of high blood pressure and its treatment and control, 1999-2008. NCHS Data Brief, 2010, 48:1-8. 被引量：1
6McAlister FA, Wilkins K, Joffres M, et al. Changes in the rates of awareness, treatment and control of hypertension in Canada over the past two decades. CMAJ. 2011,183:1007-1013. 被引量：1
7Gee ME, Bienek A, Campbell NR, et al. Prevalence of, and barriers to, preventive Lifestyle Behaviors in Hypertension (from a national survey of canadians with hypertension) [J]. Am J Cardiol, 2012, 109 (4):570-575. 被引量：1
8Hermida RC, Ayala DE, Moj6n A, et al. Chronotherapy with nifedipine GITS in hypertensive patients: improved efficacy and safety with bedtime dosing [J]. American journal of hypertension, 2008, 21(8): 948-954. 被引量：1
9SugiuraT, Kondo T, Kureishi-Bando Y, Nifedipine improves endothelial function role of endothelial progenitor cells [J]. Hypertension, 2008, 52(3):491-498. 被引量：1
